McCabe J B, Sagerman R H
Cancer. 1979 Mar;43(3):1052-7. doi: 10.1002/1097-0142(197903)43:3<1052::aid-cncr2820430340>3.0.co;2-m.
Three hundred seventy-nine consecutive patients with adenocarcinoma of the corpus uteri, in whom irradiation was part of the treatment, were reviewed. The minimum follow-up was 3 years and none were lost. An increased incidence of corpus cancer in Central New York was demonstrated but could not be attributed to estrogen usage. There were 310 patients in FIGO stage I and 40 in stage II. Adenocarcinoma was reported in 319 and adenoacanthoma in 45. Overall survival was 74% and 62% at 5 and 10 years, respectively, and in stage I, 82% and 68%, respectively. Results for adenoacanthoma were similar to those for adenocarcinoma. Ten year survival was significantly better in those patients with a histologically negative hysterectomy specimen after preoperative intracavitary irradiation than in those with residual cancer. Treatment was tolerated well. This study demonstrates the results which can be obtained in a regional radiation therapy center serving patients and gynecologists from a wide geographic region operated upon in many different hospitals.
对379例接受放射治疗的子宫体腺癌患者进行了回顾性研究。这些患者为连续入选，最短随访时间为3年，无一失访。纽约中部子宫癌发病率有所上升，但不能归因于雌激素的使用。国际妇产科联盟（FIGO）分期I期患者310例，II期患者40例。腺癌319例，腺棘癌45例。总体5年和10年生存率分别为74%和62%，I期分别为82%和68%。腺棘癌的结果与腺癌相似。术前腔内照射后子宫切除标本组织学检查阴性的患者10年生存率明显高于有残留癌的患者。治疗耐受性良好。本研究展示了在一个区域放射治疗中心所能获得的结果，该中心为来自广泛地理区域、在许多不同医院接受手术的患者和妇科医生提供服务。
